# Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus

> **NCT04100473** · PHASE2 · COMPLETED · sponsor: **Dance Biopharm Inc.** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Inhaled Human Insulin
- **DRUG:** Insulin Lispro (Humalog U-100)

## Key facts

- **NCT ID:** NCT04100473
- **Lead sponsor:** Dance Biopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-23
- **Primary completion:** 2018-08-11
- **Final completion:** 2019-08-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04100473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04100473, "Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04100473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*